Tandem Diabetes Care, Inc. Stock

Equities

TNDM

US8753722037

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
51.23 USD -4.12% Intraday chart for Tandem Diabetes Care, Inc. -0.97% +73.19%
Sales 2024 * 869M Sales 2025 * 960M Capitalization 3.31B
Net income 2024 * -109M Net income 2025 * -72M EV / Sales 2024 * 3.64 x
Net cash position 2024 * 145M Net cash position 2025 * 111M EV / Sales 2025 * 3.33 x
P/E ratio 2024 *
-31.3 x
P/E ratio 2025 *
-46.9 x
Employees 2,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.23%
More Fundamentals * Assessed data
Dynamic Chart
Redburn Atlantic Starts Tandem Diabetes Care With Buy Rating, $60 Price Target MT
Transcript : Tandem Diabetes Care, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 11:20 AM
Lake Street Adjusts Price Target on Tandem Diabetes Care to $75 From $60, Maintains Buy Rating MT
Stifel Adjusts Price Target on Tandem Diabetes Care to $55 From $45, Maintains Buy Rating MT
Citi Upgrades Tandem Diabetes Care to Buy, Price Target at $57 MT
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Wednesday; Hims & Hers Health, Tesla to Decline MT
Tandem Diabetes Care, Inc. and Unomedical a/s Enter into Amendment Number 1 to Distributor Agreement CI
Transcript : Tandem Diabetes Care, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM
Sector Update: Health Care Stocks Mixed in Afternoon Trading MT
Tandem Diabetes Care Shares Rise After Q1 Net Loss Shrinks, Sales Rise; Q2, 2024 Sales Guidance Set MT
UBS Adjusts Price Target on Tandem Diabetes Care to $40 From $28, Maintains Neutral Rating MT
Transcript : Tandem Diabetes Care, Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (TNDM) TANDEM DIABETES CARE Reports Q1 Revenue $191.7M, vs. Street Est of $173.5M MT
Tandem Diabetes Care, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
North American Morning Briefing : More Earnings -2- DJ
More news
1 day-4.12%
1 week-0.97%
1 month+39.63%
3 months+92.38%
6 months+153.11%
Current year+73.19%
More quotes
1 week
50.82
Extreme 50.82
53.69
1 month
34.43
Extreme 34.43
53.69
Current year
21.85
Extreme 21.85
53.69
1 year
13.82
Extreme 13.82
53.69
3 years
13.82
Extreme 13.82
155.86
5 years
13.82
Extreme 13.82
155.86
10 years
2.14
Extreme 2.14
186.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 13-02-28
Director of Finance/CFO 51 13-08-31
Compliance Officer 58 21-12-31
Members of the board TitleAgeSince
Chairman 63 19-01-02
Director/Board Member 64 13-06-30
Chief Executive Officer 68 13-02-28
More insiders
Date Price Change Volume
24-05-31 51.23 -4.12% 1,425,696
24-05-30 53.43 +3.25% 1,520,380
24-05-29 51.75 -2.17% 897,077
24-05-28 52.9 +2.26% 1,125,972
24-05-24 51.73 +4.13% 1,037,730

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes
Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company, which manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of it AID systems, it offers pump integration with multiple CGM sensors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
51.23 USD
Average target price
49.2 USD
Spread / Average Target
-3.96%
Consensus